Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a slower heartbeat boost quality of life for heart patients?

NCT ID NCT07205679

Knowledge-focused Sponsor: Habib Khan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 40 adults with atrial fibrillation and heart failure to see if lowering their resting heart rate from 100-110 bpm to a more normal level improves exercise ability and quality of life. Participants will do treadmill tests before and after either a cardioversion (electric shock to reset heart rhythm) or a pacemaker plus ablation procedure. The goal is to learn whether current heart rate targets are too high for these patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who have been clinically scheduled for either a P\&A or a cardioversion procedure.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 2. Persistent or Permanent Atrial Fibrillation 3. HF - NYHA class II-IVA despite guideline-direct medical therapy 4. Rate controlled 5. Able to perform stress test 6. Scheduled for clinical P\&A OR cardioversion Exclusion Criteria: 1. Creatinine \>180 μmol/L or eGFR \<30 mL/min/1.73 m2 2. Significant valvular heart disease: Moderate to severe tricuspid regurgitation, mitral regurgitation, mitral stenosis, aortic regurgitation, aortic stenosis 3. Patients who have had a TAVI, valvular surgery, or CABG within 3 months of enrolment 4. Right ventricular systolic pressure \>50mmHg 5. Existing pacemaker 6. In sinus rhythm 7. Predictable vasovagal syncope to pain and sight of blood

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ablation therapy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation heart failure persistent atrial fibrillation symptomatic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ablation therapy Atrial fibrillation (AF) Cardioversion Heart failure - nyha ii - iv Pacemaker

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.